Moffitt Cancer Center Receives $47.3 Million Federal Grant for Radiopharmaceutical Advancement
Moffitt Cancer Center's Florida Oncology and Radiopharmaceutical Growth Engine (FORGE) initiative has been awarded $47.3 million in federal funding to advance radiopharmaceutical innovation and treatment within the Tampa Bay region.
Tampa St. Petersburg, FL, November 6, 2026 — Moffitt Cancer Center has announced that its Florida Oncology and Radiopharmaceutical Growth Engine (FORGE) initiative has secured substantial federal funding. The initiative has been awarded $47.3 million to propel advancements in radiopharmaceutical innovation and treatment.
The funding is designated to enhance the development and application of radiopharmaceuticals, a specialized area of cancer treatment that utilizes radioactive drugs to diagnose and treat cancer. This significant investment is expected to bolster research and clinical capabilities within the Tampa Bay region.
The FORGE initiative at Moffitt Cancer Center aims to foster a robust ecosystem for radiopharmaceutical development. This includes supporting the entire pipeline from early-stage research and discovery through to clinical trials and eventual patient treatment. By centralizing these efforts, Moffitt seeks to accelerate the translation of scientific breakthroughs into tangible therapeutic options for cancer patients.
Radiopharmaceuticals represent a growing frontier in oncology, offering targeted therapies that can potentially minimize damage to healthy tissues while effectively targeting cancerous cells. The federal funding will likely support various aspects of this work, potentially including infrastructure development, personnel recruitment, research grants, and the establishment of new treatment protocols.
The strategic location of this initiative in the Tampa Bay region underscores a commitment to building local expertise and capacity in this critical medical field. The allocation of $47.3 million signifies a major step forward for Moffitt Cancer Center’s FORGE program, positioning it to become a leading hub for radiopharmaceutical innovation and patient care.
Story summarized from the original created by Michael Connor on stpetecatalyst.com, see more information here.
